{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:10:50Z","timestamp":1785777050037,"version":"3.56.0"},"reference-count":91,"publisher":"Japan Atherosclerosis Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2022,10,1]]},"DOI":"10.5551\/jat.rv17066","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T22:12:06Z","timestamp":1659737526000},"page":"1409-1420","source":"Crossref","is-referenced-by-count":20,"title":["Optimal Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Focused Review on High Bleeding Risk"],"prefix":"10.5551","volume":"29","author":[{"given":"Yunosuke","family":"Matsuura","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Moribayashi","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kaikita","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK and Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001; 345: 494-502","DOI":"10.1056\/NEJMoa010746"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Rodriguez F and Harrington RA: Management of Antithrombotic Therapy after Acute Coronary Syndromes. N Engl J Med, 2021; 384: 452-460","DOI":"10.1056\/NEJMra1607714"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Antithrombotic Trialists\u2019 Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002; 324: 71-86","DOI":"10.1136\/bmj.324.7329.71"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Patrono C, Garcia Rodriguez LA, Landolfi R and Baigent C: Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med, 2005; 353: 2373-2383","DOI":"10.1056\/NEJMra052717"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Mangano DT and Multicenter Study of Perioperative Ischemia Research Group: Aspirin and mortality from coronary bypass surgery. N Engl J Med, 2002; 347: 1309-1317","DOI":"10.1056\/NEJMoa020798"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ and Kuntz RE: A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med, 1998; 339: 1665-1671","DOI":"10.1056\/NEJM199812033392303"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, Andersen M and Lassen AT: Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ, 2006; 333: 726","DOI":"10.1136\/bmj.38947.697558.AE"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Toyoda K, Yasaka M, Iwade K, Nagata K, Koretsune Y, Sakamoto T, Uchiyama S, Gotoh J, Nagao T, Yamamoto M, Takahashi JC, Minematsu K and Bleeding with Antithrombotic Therapy Study Group: Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. Stroke, 2008; 39: 1740-1745","DOI":"10.1161\/STROKEAHA.107.504993"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Toyoda K, Yasaka M, Nagata K, Nagao T, Gotoh J, Sakamoto T, Uchiyama S, Minematsu K and Bleeding with Antithrombotic Therapy Study Group: Antithrombotic therapy influences location, enlargement, and mortality from intracerebral hemorrhage. The Bleeding with Antithrombotic Therapy (BAT) Retrospective Study. Cerebrovasc Dis, 2009; 27: 151-159","DOI":"10.1159\/000177924"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Ueki Y, Bar S, Losdat S, Otsuka T, Zanchin C, Zanchin T, Gragnano F, Gargiulo G, Siontis GCM, Praz F, Lanz J, Hunziker L, Stortecky S, Pilgrim T, Heg D, Valgimigli M, Windecker S and Raber L: Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. EuroIntervention, 2020; 16: 371-379","DOI":"10.4244\/EIJ-D-20-00052"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Alexander JH, Wojdyla D, Vora AN, Thomas L, Granger CB, Goodman SG, Aronson R, Windecker S, Mehran R and Lopes RD: Risk\/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. Circulation, 2020; 141: 1618-1627","DOI":"10.1161\/CIRCULATIONAHA.120.046534"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ and Lip GY: A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest, 2010; 138: 1093-1100","DOI":"10.1378\/chest.10-0134"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Tarantini G, Nai Fovino L, Tellaroli P, Chieffo A, Barioli A, Menozzi A, Frasheri A, Garbo R, Masotti-Centol M, Salvatella N, Dominguez JF, Steffanon L, Presbitero P, Pucci E, Fraccaro C, Mauri J, Giustino G, Sardella G and Colombo A: Optimal duration of dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes: The SECURITY (Second-Generation Drug-Eluting Stent Implantation Followed By Six- Versus Twelve-Month Dual Antiplatelet Therapy)-diabetes substudy. Int J Cardiol, 2016; 207: 168-176","DOI":"10.1016\/j.ijcard.2016.01.068"},{"key":"14","unstructured":"14) Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB, 3rd, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ, Jr., Nicolela EL, Jr., Perin MA, Devito FS, Labrunie A, Salvadori D, Jr., Gusmao M, Staico R, Costa JR, Jr., de Castro JP, Abizaid AS, Bhatt DL and OPTIMIZE Trial Investigators: Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA, 2013; 310: 2510-2522"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Sinnaeve PR and Adriaenssens T: Dual Antiplatelet Therapy De-escalation Strategies. Am J Cardiol, 2021; 144 Suppl 1: S23-S31","DOI":"10.1016\/j.amjcard.2020.12.020"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW and Morice MC: Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation, 2019; 140: 240-261","DOI":"10.1161\/CIRCULATIONAHA.119.040167"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW and Morice MC: Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J, 2019; 40: 2632-2653","DOI":"10.1093\/eurheartj\/ehz372"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Ariotti S, Adamo M, Costa F, Patialiakas A, Briguori C, Thury A, Colangelo S, Campo G, Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Ferlini M, Vranckx P, Valgimigli M and ZEUS Investigators: Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial. JACC Cardiovasc Interv, 2016; 9: 426-436","DOI":"10.1016\/j.jcin.2015.11.015"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrie D, Naber C, Lipiecki J, Richardt G, Iniguez A, Brunel P, Valdes-Chavarri M, Garot P, Talwar S, Berland J, Abdellaoui M, Eberli F, Oldroyd K, Zambahari R, Gregson J, Greene S, Stoll HP, Morice MC and LEADERS FREE Investigators: Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. N Engl J Med, 2015; 373: 2038-2047","DOI":"10.1056\/NEJMoa1503943"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carrie D, Hovasse T, Garot P, El Mahmoud R, Spaulding C, Helft G, Diaz Fernandez JF, Brugaletta S, Pinar-Bermudez E, Mauri Ferre J, Commeau P, Teiger E, Bogaerts K, Sabate M, Morice MC, Sinnaeve PR and SENIOR investigators: Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet, 2018; 391: 41-50","DOI":"10.1016\/S0140-6736(17)32713-7"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) de Belder A, de la Torre Hernandez JM, Lopez-Palop R, O\u2019Kane P, Hernandez Hernandez F, Strange J, Gimeno F, Cotton J, Diaz Fernandez JF, Carrillo Saez P, Thomas M, Pinar E, Curzen N, Baz JA, Cooter N, Lozano I, Skipper N, Robinson D, Hildick-Smith D and XIMA Investigators: A prospective randomized trial of everolimus-eluting stents versus bare-metal stents in octogenarians: the XIMA Trial (Xience or Vision Stents for the Management of Angina in the Elderly). J Am Coll Cardiol, 2014; 63: 1371-1375","DOI":"10.1016\/j.jacc.2013.10.053"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Costa F, van Klaveren D, James S, Heg D, Raber L, Feres F, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M and PRECISE-DAPT Study Investigators: Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet, 2017; 389: 1025-1034","DOI":"10.1016\/S0140-6736(17)30397-5"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L and DAPT Study Investigators: Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA, 2016; 315: 1735-1749","DOI":"10.1001\/jama.2016.3775"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, Ariti C, Litherland C, Dangas G, Gibson CM, Krucoff MW, Moliterno DJ, Kirtane AJ, Stone GW, Colombo A, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG and Pocock S: Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. J Am Coll Cardiol, 2016; 67: 2224-2234","DOI":"10.1016\/j.jacc.2016.02.064"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Natsuaki M, Morimoto T, Yamaji K, Watanabe H, Yoshikawa Y, Shiomi H, Nakagawa Y, Furukawa Y, Kadota K, Ando K, Akasaka T, Hanaoka KI, Kozuma K, Tanabe K, Morino Y, Muramatsu T, Kimura T, Credo-Kyoto PCI\/CABG Registry Cohort 2, RESET, and NEXT trial investigators: Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO-Kyoto Thrombotic and Bleeding Risk Scores. J Am Heart Assoc, 2018; 7: e008708.","DOI":"10.1161\/JAHA.118.008708"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Cao D, Mehran R, Dangas G, Baber U, Sartori S, Chandiramani R, Stefanini GG, Angiolillo DJ, Capodanno D, Urban P, Morice MC, Krucoff M, Goel R, Roumeliotis A, Sweeny J, Sharma SK and Kini A: Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. J Am Coll Cardiol, 2020; 75: 2711-2722","DOI":"10.1016\/j.jacc.2020.03.070"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Corpataux N, Spirito A, Gragnano F, Vaisnora L, Galea R, Svab S, Gargiulo G, Zanchin T, Zanchin C, Siontis GCM, Praz F, Lanz J, Hunziker L, Stortecky S, Pilgrim T, Raber L, Capodanno D, Urban P, Pocock S, Heg D, Windecker S and Valgimigli M: Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. Eur Heart J, 2020; 41: 3743-3749","DOI":"10.1093\/eurheartj\/ehaa671"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Natsuaki M, Morimoto T, Shiomi H, Yamaji K, Watanabe H, Shizuta S, Kato T, Ando K, Nakagawa Y, Furukawa Y, Tada T, Nagao K, Kadota K, Toyofuku M and Kimura T: Application of the Academic Research Consortium High Bleeding Risk Criteria in an All-Comers Registry of Percutaneous Coronary Intervention. Circ Cardiovasc Interv, 2019; 12: e008307","DOI":"10.1161\/CIRCINTERVENTIONS.119.008307"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Nakamura M, Kadota K, Takahashi A, Kanda J, Anzai H, Ishii Y, Shibata Y, Yasaka Y, Takamisawa I, Yamaguchi J, Takeda Y, Harada A, Motohashi T, Iijima R, Uemura S, Murakami Y and PENDULUM Investigators*: Relationship Between Platelet Reactivity and Ischemic and Bleeding Events After Percutaneous Coronary Intervention in East Asian Patients: 1-Year Results of the PENDULUM Registry. J Am Heart Assoc, 2020; 9: e015439","DOI":"10.1161\/JAHA.119.015439"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Kang J, Park KW, Palmerini T, Stone GW, Lee MS, Colombo A, Chieffo A, Feres F, Abizaid A, Bhatt DL, Valgimigli M, Hong MK, Jang Y, Gilard M, Morice MC, Park DW, Park SJ, Jeong YH, Park J, Koo BK and Kim HS: Racial Differences in Ischaemia\/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs. Thromb Haemost, 2019; 119: 149-162","DOI":"10.1055\/s-0038-1676545"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R, for the RAVEL Study Group: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med, 2002; 346: 1773-1780","DOI":"10.1056\/NEJMoa012843"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O\u2019Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE and SIRIUS Investigators: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med, 2003; 349: 1315-1323","DOI":"10.1056\/NEJMoa035071"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R and Serruys PW: Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet, 2004; 364: 1519-1521","DOI":"10.1016\/S0140-6736(04)17275-9"},{"key":"34","unstructured":"34) Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E and Colombo A: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA, 2005; 293: 2126-2130"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C and BASKET-LATE Investigators: Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol, 2006; 48: 2584-2591","DOI":"10.1016\/j.jacc.2006.10.026"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Kadota K, Yamaji K, Ando K, Shizuta S, Shiomi H, Tada T, Tazaki J, Kato Y, Hayano M, Abe M, Tamura T, Shirotani M, Miki S, Matsuda M, Takahashi M, Ishii K, Tanaka M, Aoyama T, Doi O, Hattori R, Kato M, Suwa S, Takizawa A, Takatsu Y, Shinoda E, Eizawa H, Takeda T, Lee JD, Inoko M, Ogawa H, Hamasaki S, Horie M, Nohara R, Kambara H, Fujiwara H, Mitsudo K, Nobuyoshi M, Kita T, Kimura T: Late adverse events after implantation of sirolimus-eluting stent and bare-metal stent: long-term (5-7 years) follow-up of the Coronary Revascularization Demonstrating Outcome study-Kyoto registry Cohort-2. Circ Cardiovasc Interv, 2014; 7: 168-179","DOI":"10.1161\/CIRCINTERVENTIONS.113.000987"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R and Leon MB: Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med, 2007; 356: 998-1008","DOI":"10.1056\/NEJMoa067193"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK and Virmani R: Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007; 115: 2435-2441","DOI":"10.1161\/CIRCULATIONAHA.107.693739"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK and Virmani R: Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol, 2006; 48: 193-202","DOI":"10.1016\/j.jacc.2006.03.042"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, Mintz GS and Nagata S: Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol, 2006; 47: 2108-2111","DOI":"10.1016\/j.jacc.2005.11.092"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Awata M, Kotani J, Uematsu M, Morozumi T, Watanabe T, Onishi T, Iida O, Sera F, Nanto S, Hori M and Nagata S: Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation, 2007; 116: 910-916","DOI":"10.1161\/CIRCULATIONAHA.105.609057"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O and Kolodgie FD: Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation, 2004; 109: 701-705","DOI":"10.1161\/01.CIR.0000116202.41966.D4"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, Davidson CJ, McKoy JM, Raisch DW, Whisenant BK, Yarnold PR, Belknap SM, West DP, Gage JE, Morse RE, Gligoric G, Davidson L and Feldman MD: Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol, 2006; 47: 175-181","DOI":"10.1016\/j.jacc.2005.07.071"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Palmerini T, Benedetto U, Bacchi-Reggiani L, Della Riva D, Biondi-Zoccai G, Feres F, Abizaid A, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Genereux P, Bhatt DL, Orlandi C, De Servi S, Petrou M, Rapezzi C and Stone GW: Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet, 2015; 385: 2371-2382","DOI":"10.1016\/S0140-6736(15)60263-X"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ and SPIRIT IV Investigators: Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med, 2010; 362: 1663-1674","DOI":"10.1056\/NEJMoa0910496"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS, Jr., Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ and Stone GW: Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv, 2013; 6: 914-922","DOI":"10.1016\/j.jcin.2013.05.005"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Baber U, Mehran R, Sharma SK, Brar S, Yu J, Suh JW, Kim HS, Park SJ, Kastrati A, de Waha A, Krishnan P, Moreno P, Sweeny J, Kim MC, Suleman J, Pyo R, Wiley J, Kovacic J, Kini AS and Dangas GD: Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol, 2011; 58: 1569-1577","DOI":"10.1016\/j.jacc.2011.06.049"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Tada T, Byrne RA, Simunovic I, King LA, Cassese S, Joner M, Fusaro M, Schneider S, Schulz S, Ibrahim T, Ott I, Massberg S, Laugwitz KL and Kastrati A: Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv, 2013; 6: 1267-1274","DOI":"10.1016\/j.jcin.2013.06.015"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Navarese EP, Andreotti F, Schulze V, Kolodziejczak M, Buffon A, Brouwer M, Costa F, Kowalewski M, Parati G, Lip GY, Kelm M and Valgimigli M: Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ, 2015; 350: h1618","DOI":"10.1136\/bmj.h1618"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Bularga A, Meah MN, Doudesis D, Shah ASV, Mills NL, Newby DE and Lee KK: Duration of dual antiplatelet therapy and stability of coronary heart disease: a 60 000-patient meta-analysis of randomised controlled trials. Open Heart, 2021; 8:","DOI":"10.1136\/openhrt-2021-001707"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) El-Hayek G, Bangalore S, Casso Dominguez A, Devireddy C, Jaber W, Kumar G, Mavromatis K, Tamis-Holland J and Samady H: Meta-Analysis of Randomized Clinical Trials Comparing Biodegradable Polymer Drug-Eluting Stent to Second-Generation Durable Polymer Drug-Eluting Stents. JACC Cardiovasc Interv, 2017; 10: 462-473","DOI":"10.1016\/j.jcin.2016.12.002"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Mehran R, Cao D, Angiolillo DJ, Bangalore S, Bhatt DL, Ge J, Hermiller J, Makkar RR, Neumann FJ, Saito S, Picon H, Toelg R, Maksoud A, Chehab BM, De la Torre Hernandez JM, Kunadian V, Sardella G, Thiele H, Varenne O, Vranckx P, Windecker S, Zhou Y, Krucoff MW, Ruster K, Wang J, Valgimigli M: 3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation. JACC Cardiovasc Interv, 2021; 14: 1870-1883","DOI":"10.1016\/j.jcin.2021.07.016"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Valgimigli M, Frigoli E, Heg D, Tijssen J, Juni P, Vranckx P, Ozaki Y, Morice MC, Chevalier B, Onuma Y, Windecker S, Tonino PAL, Roffi M, Lesiak M, Mahfoud F, Bartunek J, Hildick-Smith D, Colombo A, Stankovic G, Iniguez A, Schultz C, Kornowski R, Ong PJL, Alasnag M, Rodriguez AE, Moschovitis A, Laanmets P, Donahue M, Leonardi S, Smits PC and MASTER DAPT Investigators: Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. N Engl J Med, 2021; 385: 1643-1655","DOI":"10.1056\/NEJMoa2108749"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, Ohya M, Suwa S, Takagi K, Nanasato M, Hata Y, Yagi M, Suematsu N, Yokomatsu T, Takamisawa I, Doi M, Noda T, Okayama H, Seino Y, Tada T, Sakamoto H, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Hanaoka KI, Morino Y, Kozuma K, Kadota K, Furukawa Y, Nakagawa Y, Kimura T and STOPDAPT-2 Investigators: Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA, 2019; 321: 2414-2427","DOI":"10.1001\/jama.2019.8145"},{"key":"55","unstructured":"55) Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN: 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2018; 39: 213-260"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Giustino G, Chieffo A, Palmerini T, Valgimigli M, Feres F, Abizaid A, Costa RA, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Gilard M, Morice MC, Sawaya F, Sardella G, Genereux P, Redfors B, Leon MB, Bhatt DL, Stone GW and Colombo A: Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. J Am Coll Cardiol, 2016; 68: 1851-1864","DOI":"10.1016\/j.jacc.2016.07.760"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Costa F, Van Klaveren D, Feres F, James S, Raber L, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M and PRECISE-DAPT Study Investigators: Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. J Am Coll Cardiol, 2019; 73: 741-754","DOI":"10.1016\/j.jacc.2018.11.048"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Hemetsberger R, Abdelghani M, Toelg R, Garcia-Garcia HM, Farhan S, Mankerious N, Elbasha K, Allali A, Windecker S, Lefevre T, Saito S, Kandzari D, Waksman R and Richardt G: Complex vs. non-complex percutaneous coronary intervention with newer-generation drug-eluting stents: an analysis from the randomized BIOFLOW trials. Clin Res Cardiol, 2022;","DOI":"10.1007\/s00392-022-01994-4"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Jeger RV, Eccleshall S, Wan Ahmad WA, Ge J, Poerner TC, Shin ES, Alfonso F, Latib A, Ong PJ, Rissanen TT, Saucedo J, Scheller B, Kleber FX and International DCB Consensus Group: Drug-Coated Balloons for Coronary Artery Disease: Third Report of the International DCB Consensus Group. JACC Cardiovasc Interv, 2020; 13: 1391-1402","DOI":"10.1016\/j.jcin.2020.02.043"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Sato Y, Hatakeyama K, Yamashita A, Marutsuka K, Sumiyoshi A and Asada Y: Proportion of fibrin and platelets differs in thrombi on ruptured and eroded coronary atherosclerotic plaques in humans. Heart, 2005; 91: 526-530","DOI":"10.1136\/hrt.2004.034058"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Kaikita K, Ogawa H, Yasue H, Takeya M, Takahashi K, Saito T, Hayasaki K, Horiuchi K, Takizawa A, Kamikubo Y and Nakamura S: Tissue factor expression on macrophages in coronary plaques in patients with unstable angina. Arterioscler Thromb Vasc Biol, 1997; 17: 2232-2237","DOI":"10.1161\/01.ATV.17.10.2232"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Matsuura Y, Yamashita A, Iwakiri T, Sugita C, Okuyama N, Kitamura K and Asada Y: Vascular wall hypoxia promotes arterial thrombus formation via augmentation of vascular thrombogenicity. Thromb Haemost, 2015; 114: 158-172","DOI":"10.1160\/TH14-09-0794"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Moscucci M, Fox KA, Cannon CP, Klein W, Lopez-Sendon J, Montalescot G, White K and Goldberg RJ: Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J, 2003; 24: 1815-1823","DOI":"10.1016\/S0195-668X(03)00485-8"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Segev A, Strauss BH, Tan M, Constance C, Langer A, Goodman SG and Canadian Acute Coronary Syndromes Registries Investigators: Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries. Am Heart J, 2005; 150: 690-694","DOI":"10.1016\/j.ahj.2004.11.012"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O\u2019Gara PT, Sabatine MS, Smith PK and Smith SC, Jr.: 2016 ACC\/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF\/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC\/AHA\/ACP \/AATS\/PCNA \/SCAI\/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF\/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA\/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC\/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation, 2016; 134: e123-155","DOI":"10.1161\/CIR.0000000000000404"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Nakamura M, Kimura K, Kimura T, Ishihara M, Otsuka F, Kozuma K, Kosuge M, Shinke T, Nakagawa Y, Natsuaki M, Yasuda S, Akasaka T, Kohsaka S, Haze K and Hirayama A: JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease. Circ J, 2020; 84: 831-865","DOI":"10.1253\/circj.CJ-19-1109"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Valgimigli M, Cao D, Angiolillo DJ, Bangalore S, Bhatt DL, Ge J, Hermiller J, Makkar RR, Neumann FJ, Saito S, Picon H, Toelg R, Maksoud A, Chehab BM, Choi JW, Campo G, De la Torre Hernandez JM, Kunadian V, Sardella G, Thiele H, Varenne O, Vranckx P, Windecker S, Zhou Y, Krucoff MW, Ruster K, Zheng Y, Mehran R: Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI. J Am Coll Cardiol, 2021; 78: 2060-2072","DOI":"10.1016\/j.jacc.2021.08.074"},{"key":"68","unstructured":"68) Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Ogita M, Suwa S, Isawa T, Domei T, Yamaji K, Tatsushima S, Watanabe H, Ohya M, Tokuyama H, Tada T, Sakamoto H, Mori H, Suzuki H, Nishikura T, Wakabayashi K, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Morino Y, Kadota K, Furukawa Y, Nakagawa Y, Kimura T and STOPDAPT-2 ACS Investigators: Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. JAMA Cardiol, 2022; 7: 407-417"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Holmes MV, Perel P, Shah T, Hingorani AD and Casas JP: CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA, 2011; 306: 2704-2714","DOI":"10.1001\/jama.2011.1880"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van \u2018t Hof AWJ, van der Harst P, Barbato E, Morisco C, Tjon Joe Gin RM, Asselbergs FW, Mosterd A, Herrman JR, Dewilde WJM, Janssen PWA, Kelder JC, Postma MJ, de Boer A, Boersma C, Deneer VHM and Ten Berg JM: A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. N Engl J Med, 2019; 381: 1621-1631","DOI":"10.1056\/NEJMoa1907096"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Pereira NL, Farkouh ME, So D, Lennon R, Geller N, Mathew V, Bell M, Bae JH, Jeong MH, Chavez I, Gordon P, Abbott JD, Cagin C, Baudhuin L, Fu YP, Goodman SG, Hasan A, Iturriaga E, Lerman A, Sidhu M, Tanguay JF, Wang L, Weinshilboum R, Welsh R, Rosenberg Y, Bailey K and Rihal C: Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. JAMA, 2020; 324: 761-771","DOI":"10.1001\/jama.2020.12443"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, Bestehorn HP, Buttner HJ and Neumann FJ: Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol, 2010; 55: 2427-2434","DOI":"10.1016\/j.jacc.2010.02.031"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM and investigators T-T: Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet, 2009; 373: 723-731","DOI":"10.1016\/S0140-6736(09)60441-4"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S and Nakamura M: Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J, 2014; 78: 1684-1692","DOI":"10.1253\/circj.CJ-13-1482"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Ikeda Y, Nakamura M, Saito S and Investigators PR-E: Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention. Circ J, 2014; 78: 2926-2934","DOI":"10.1253\/circj.CJ-14-0266"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M; PLATO Investigators: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2009; 361: 1045-1057","DOI":"10.1056\/NEJMoa0904327"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Schupke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wohrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, Akin I, Bott-Flugel L, Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M, Boncompagni D, Hilz R, Rottbauer W, Okrojek R, Mollmann H, Hochholzer W, Migliorini A, Cassese S, Mollo P, Xhepa E, Kufner S, Strehle A, Leggewie S, Allali A, Ndrepepa G, Schuhlen H, Angiolillo DJ, Hamm CW, Hapfelmeier A, Tolg R, Trenk D, Schunkert H, Laugwitz KL, Kastrati A and ISAR-REACT 5 Trial Investigators: Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med, 2019; 381: 1524-1534","DOI":"10.1056\/NEJMoa1908973"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Sorensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK and Olsen JH: Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol, 2000; 95: 2218-2224","DOI":"10.1111\/j.1572-0241.2000.02248.x"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Chiarito M, Sanz-Sanchez J, Cannata F, Cao D, Sturla M, Panico C, Godino C, Regazzoli D, Reimers B, De Caterina R, Condorelli G, Ferrante G and Stefanini GG: Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet, 2020; 395: 1487-1495","DOI":"10.1016\/S0140-6736(20)30315-9"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) O\u2019Donoghue ML, Murphy SA and Sabatine MS: The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Circulation, 2020; 142: 538-545","DOI":"10.1161\/CIRCULATIONAHA.120.046251"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81) Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, Cha JY, Collier T, Dangas G, Dudek D, Dzavik V, Escaned J, Gil R, Gurbel P, Hamm CW, Henry T, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff M, Kunadian V, Marx SO, Mehta SR, Moliterno D, Ohman EM, Oldroyd K, Sardella G, Sartori S, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han YL, Pocock S and Gibson CM: Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med, 2019; 381: 2032-2042","DOI":"10.1056\/NEJMoa1908419"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Hess CN, Peterson ED, Peng SA, de Lemos JA, Fosbol EL, Thomas L, Bhatt DL, Saucedo JF and Wang TY: Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation. J Am Coll Cardiol, 2015; 66: 616-627","DOI":"10.1016\/j.jacc.2015.05.062"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrom SZ, Poulsen HE, Kober L and Torp-Pedersen C: Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med, 2010; 170: 1433-1441","DOI":"10.1001\/archinternmed.2010.271"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84) Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van \u2018t Hof AW, ten Berg JM and WOEST study investigators: Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet, 2013; 381: 1107-1115","DOI":"10.1016\/S0140-6736(12)62177-1"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85) Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED and Fox KA: Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med, 2016; 375: 2423-2434","DOI":"10.1056\/NEJMoa1611594"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86) Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH: Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med, 2017; 377: 1513-1524","DOI":"10.1056\/NEJMoa1708454"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87) Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, Batushkin V, Campo G, Lysak Z, Vakaliuk I, Milewski K, Laeis P, Reimitz PE, Smolnik R, Zierhut W and Goette A: Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet, 2019; 394: 1335-1343","DOI":"10.1016\/S0140-6736(19)31872-0"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman SG, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj A, Hijazi Z, Parkhomenko A, Sinnaeve P, Storey RF, Thiele H, Vinereanu D, Granger CB, Alexander JH and AUGUSTUS Investigators: Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med, 2019; 380: 1509-1524","DOI":"10.1056\/NEJMoa1817083"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89) Matsumura-Nakano Y, Shizuta S, Komasa A, Morimoto T, Masuda H, Shiomi H, Goto K, Nakai K, Ogawa H, Kobori A, Kono Y, Kaitani K, Suwa S, Aoyama T, Takahashi M, Sasaki Y, Onishi Y, Mano T, Matsuda M, Motooka M, Tomita H, Inoko M, Wakeyama T, Hagiwara N, Tanabe K, Akao M, Miyauchi K, Yajima J, Hanaoka K, Morino Y, Ando K, Furukawa Y, Nakagawa Y, Nakao K, Kozuma K, Kadota K, Kimura K, Kawai K, Ueno T, Okumura K, Kimura T and OAC-ALONE Study Investigators: Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation. Circulation, 2019; 139: 604-616","DOI":"10.1161\/CIRCULATIONAHA.118.036768"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H and AFIRE Investigators: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med, 2019; 381: 1103-1113","DOI":"10.1056\/NEJMoa1904143"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Kaikita K, Hosokawa K, Dahlen JR and Tsujita K: Total Thrombus-Formation Analysis System (T-TAS): Clinical Application of Quantitative Analysis of Thrombus Formation in Cardiovascular Disease. Thromb Haemost, 2019; 119: 1554-1562","DOI":"10.1055\/s-0039-1693411"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/29\/10\/29_RV17066\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T04:46:36Z","timestamp":1664599596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/29\/10\/29_RV17066\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":91,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.rv17066","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,1]]},"article-number":"RV17066"}}